Related Experiment Video
Updated: Nov 30, 2025
08:35
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
8.2K
Targeting Bcl-2 Family Proteins: What, Where, When?
V V Senichkin1, N V Pervushin1, A P Zuev1
1Faculty of Basic Medicine, Lomonosov Moscow State University, Moscow, 119192, Russia.
Biochemistry. Biokhimiia
|November 17, 2020
Summary
Targeting antiapoptotic Bcl-2 family proteins offers a promising strategy for cancer therapy. Inhibitors are being developed to overcome tumor resistance and improve patient outcomes in precision medicine.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- The Bcl-2 protein family regulates apoptosis, a critical process in cell death.
- Tumor cells exploit antiapoptotic proteins to evade death, contributing to cancer development and therapeutic resistance.
- Antiapoptotic Bcl-2 proteins are attractive targets for novel cancer therapies.
Purpose of the Study:
- To review the mechanisms of Bcl-2 family protein function and inhibition.
- To discuss the success of Bcl-2 inhibitors in cancer treatment.
- To explore biochemical features for improving Bcl-2 inhibitor efficacy.
Main Methods:
- Review of scientific literature on Bcl-2 family proteins and their inhibitors.
- Analysis of preclinical and clinical studies of Bcl-2 targeted agents.
- Investigation of molecular mechanisms of drug sensitivity and resistance.
Main Results:
- Development of highly selective small molecule inhibitors targeting antiapoptotic Bcl-2 members.
- Clinical success of venetoclax, a Bcl-2 inhibitor, highlights therapeutic potential.
- Ongoing research into optimizing inhibitor combinations and understanding resistance mechanisms.
Conclusions:
- Inhibition of antiapoptotic Bcl-2 proteins is a validated and evolving cancer therapeutic strategy.
- Precision medicine approaches are crucial for identifying optimal patient populations and treatment combinations.
- Further research into Bcl-2 family protein interactions and inhibitor biochemistry will enhance anticancer drug development.
Related Concept Videos
02:57Targeted Cancer Therapies
8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.2K
01:31The Intrinsic Apoptotic Pathway
7.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.6K
02:50Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
02:34Inhibition of Cdk Activity
5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
02:15M-Cdk Drives Transition Into Mitosis
6.0K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
01:22PI3K/mTOR/AKT Signaling Pathway
4.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.8K